Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

241 trials with published results (19%)

Research Maturity

819 completed trials (65% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.1%

90 terminated out of 1265 trials

Success Rate

90.1%

+3.6% vs benchmark

Late-Stage Pipeline

15%

188 trials in Phase 3/4

Results Transparency

29%

241 of 819 completed with results

Key Signals

241 with results90% success90 terminated

Data Visualizations

Phase Distribution

966Total
Not Applicable (394)
Early P 1 (16)
P 1 (165)
P 2 (203)
P 3 (113)
P 4 (75)

Trial Status

Completed819
Unknown163
Terminated90
Recruiting86
Withdrawn45
Active Not Recruiting28

Trial Success Rate

90.1%

Benchmark: 86.5%

Based on 819 completed trials

Clinical Trials (1265)

Showing 20 of 20 trials
NCT07174310Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07569133Not ApplicableEnrolling By InvitationPrimary

Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease

NCT07570212Not ApplicableRecruitingPrimary

Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders

NCT04232969Phase 3CompletedPrimary

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

NCT01399411Completed

Agricultural Health Study Follow-up

NCT02119611Not ApplicableRecruitingPrimary

Deep Brain Stimulation Therapy in Movement Disorders

NCT00024622Completed

PET Scanning in Parkinson s Disease

NCT07441915Not ApplicableRecruitingPrimary

Auditory Sleep Stimulation or Sham in People With Parkinson Disease Mild Cognitive Impairment During Cognitive Training

NCT03648905Active Not RecruitingPrimary

Clinical Laboratory Evaluation of Chronic Autonomic Failure

NCT04396873Phase 1RecruitingPrimary

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

NCT01581580Not ApplicableRecruitingPrimary

Deep Brain Stimulation Surgery for Movement Disorders

NCT05830110Not ApplicableActive Not RecruitingPrimary

Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease

NCT06562569Not ApplicableRecruitingPrimary

Non-invasive VNS for Parkinson's Gait

NCT02360683CompletedPrimary

Predictive Factors and Subthalamic Stimulation in Parkinson's Disease

NCT03836950Phase 1RecruitingPrimary

rTMS to Improve Cognition in Parkinson's

NCT07371338Phase 1Recruiting

Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

NCT07330258RecruitingPrimary

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

NCT02246374Not ApplicableCompletedPrimary

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease

NCT07536022Not ApplicableNot Yet RecruitingPrimary

At-home taVNS for Neurorehabilitation in Parkinson's Disease

NCT07533799RecruitingPrimary

The Swedish BioFINDER Sleep Study

Scroll to load more

Research Network

Activity Timeline